Trials / Active Not Recruiting
Active Not RecruitingNCT03738553
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 13 (actual)
- Sponsor
- University of Washington · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.
Detailed description
This is not a treatment trial. Patients will be treated according to the plan developed by their medical oncologists. Only patients planning to receive anti-HER2 therapy as part of planned systemic therapy will be eligible for this imaging study. Patients and their referring oncologist will be asked to start the anti-HER2 therapy 2-3 weeks prior to surgery and after the pre-therapy MRI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRI | Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI |
| DRUG | Trastuzumab | Single dose of Trastuzumab prior to surgery |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2020-09-01
- Completion
- 2026-03-01
- First posted
- 2018-11-13
- Last updated
- 2025-10-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03738553. Inclusion in this directory is not an endorsement.